Editorial commentary: Gatifloxacin therapy for children: An antibiotic still in the "back room"

Clinical Infectious Diseases

Volumn 41, Issue 4, 2005, Pages 479-480

  Marchant, Colin D ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; GATIFLOXACIN; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ARTHROPATHY; CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; OTITIS MEDIA; PRIORITY JOURNAL; CHILD; DRUG APPROVAL; NOTE;

ANTI-INFECTIVE AGENTS; CHILD; DRUG APPROVAL; FLUOROQUINOLONES; HUMANS; OTITIS MEDIA;

EID: 23244460698     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431596     Document Type: Editorial

References (7)

1. Finkelstein JA, Stille C, Nordin J, et al. Reduction in antibiotic use among US children, 1996-2000. Pediatrics 2003; 112:620-7.
2. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1-9.
3. Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005; 41:470-8 (in this issue).
4. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J 2003; 22:943-9.
5. Yee CL, Duffy C, Gerbino PG, et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21:525-9.
6. US Food and Drug Administration. Notice of cancellation of the 10 May 2004 meeting of the Anti-Infective Drugs Advisory Committee. Available at: http://www.fda.gov/oc/advisory /accalendar/2004/cder12530d051004.html. Accessed 9 June 2005.
7. US Food and Drug Administration Advisory Committee. Bristol Tequin meeting for recurrent otitis media cancelled after sponsor pulls sNDA. 30 April 2004. Available at: http://www .fdaadvisorycommittee.com/FDC/AdvisoryCom mittee/Stories/051004_TequinCancelled.htm. Accessed 9 June 2005.